

# Erin M Guest

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8369634/publications.pdf>

Version: 2024-02-01

28  
papers

616  
citations

687363

13  
h-index

677142

22  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1291  
citing authors

#	ARTICLE	IF	CITATIONS
1	Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. <i>Nature Reviews Cancer</i> , 2010, 10, 721-728.	28.4	151
2	The Super Elongation Complex Family of RNA Polymerase II Elongation Factors: Gene Target Specificity and Transcriptional Output. <i>Molecular and Cellular Biology</i> , 2012, 32, 2608-2617.	2.3	150
3	Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric <i>KMT2A</i> -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , 2021, 39, 3149-3160.	1.6	40
4	Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in <i>KMT2A</i> -rearranged leukemia. <i>Blood</i> , 2022, 139, 2198-2211.	1.4	37
5	Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. <i>Clinical Cancer Research</i> , 2020, 26, 2297-2307.	7.0	28
6	Emergency medical genomes: a breakthrough application of precision medicine. <i>Genome Medicine</i> , 2015, 7, 82.	8.2	25
7	Updates in the biology and therapy for infant acute lymphoblastic leukemia. <i>Current Opinion in Pediatrics</i> , 2017, 29, 20-26.	2.0	23
8	Landscape of Somatic Mutations and Gene Expression Changes in Relapsed Infant MLL-Rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 1735-1735.	1.4	22
9	Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 4251-4255.	5.2	20
10	Precision Medicine in Pediatric Cancer: Current Applications and Future Prospects. <i>High-Throughput</i> , 2018, 7, 39.	4.4	18
11	Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28062.	1.5	18
12	Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. <i>Blood</i> , 2017, 130, 943-945.	1.4	16
13	Prognostic Significance of 11q23/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531. <i>Blood</i> , 2016, 128, 1211-1211.	1.4	14
14	Outstanding outcomes in infants with <i>KMT2A</i> -germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. <i>Haematologica</i> , 2022, 107, 1205-1208.	3.5	11
15	Childhood Cancer for the Primary Care Physician. <i>Primary Care - Clinics in Office Practice</i> , 2015, 42, 43-55.	1.6	10
16	Combined heparin/acid citrate dextrose solution A anticoagulation in the Optia continuous mononuclear cell protocol for pediatric lymphocyte apheresis. <i>Journal of Clinical Apheresis</i> , 2019, 34, 487-489.	1.3	8
17	Alteration of Chromatin Modifiers and Misregulation of Transcription Factors Define the Genomic Profile of Infant AML. <i>Blood</i> , 2016, 128, 774-774.	1.4	8
18	Misleading hepatitis B testing in the setting of intravenous immunoglobulin. <i>F1000Research</i> , 2013, 2, 249.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Parental Perceptions of Obesity and Obesity Risk Associated With Childhood Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, 370-375.	0.6	4
20	Treatment of 11q23/MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Blood</i> , 2015, 126, 799-799.	1.4	3
21	Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG. <i>Blood</i> , 2021, 138, 2360-2360.	1.4	2
22	An Unusual Case of Rapidly Progressive Hyperbilirubinemia. <i>Case Reports in Pediatrics</i> , 2013, 2013, 1-3.	0.4	1
23	Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. <i>Blood</i> , 2020, 136, 26-27.	1.4	1
24	Hb Lake Tapawingo [ $\epsilon$ 46(CE4)Phe $\alpha$ 1'Ser; HBA2:c.140T $\rightarrow$ C]: A New Unstable $\beta$ Chain Hemoglobin Variant Associated with Low Systemic Arterial Saturation. <i>Hemoglobin</i> , 2011, 35, 411-416.	0.8	0
25	Neonatal Leukemia. , 2021, , 367-381.		0
26	Whole Genome Bisulfite Sequencing (WGBS) Robustly Measures the Pharmacodynamic Effect of Decitabine/Vorinostat Epigenetic Treatment in Relapsed Pediatric ALL Demonstrating Potent Hypomethylation Associated with Upregulation of PRC2 and TP53 Targets. <i>Blood</i> , 2018, 132, 918-918.	1.4	0
27	Single-Cell Multiomics Reveals Increased Plasticity, Resistant Populations and Stem-Cell-like Blasts in KMT2A-Rearranged Leukemia. <i>Blood</i> , 2021, 138, 2203-2203.	1.4	0
28	Germline Variants Associated with Cancer Predisposition and Bone Marrow Failure Are Common in KMT2A-r Infant Acute Lymphoblastic Leukemia Patients. <i>Blood</i> , 2020, 136, 41-41.	1.4	0